靶向B淋巴细胞治疗系统性红斑狼疮的生物制剂:贝利尤单抗与泰它西普

B-lymphocyte-targeted biologics for systemic lupus erythematosus:belimumab and telitacicept

目前国内批准用于系统性红斑狼疮的以B淋巴细胞为治疗靶点的生物制剂仅有贝利尤单抗和泰它西普。本文通过比较两种生物制剂的作用机制、用法用量、药代动力学、有效性、安全性等方面的数据,以便临床更全面地了解两个药物。

At present,the biological agents approved for the treatment of systemic lupus erythematosus with B lymphocyte as the therapeutic target included belimumab and telitacicept.This article compared the mechanism of action,usage and dosage,pharmacokinetics,effectiveness,safety and other data of the two biological agents to more comprehensively understanding the two drugs.